Melrose, MA, United States of America

Richard Caldwell

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Foghorn Therapeutics Inc.. Active years: 2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Caldwell. Retrieved from https://idiyas.com/inventor/richard-caldwell-362gas4i

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Richard Caldwell: Innovator in Pharmaceutical Compounds

Introduction

Richard Caldwell is a notable inventor based in Melrose, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have potential therapeutic uses.

Latest Patents

Caldwell holds a patent for "Compounds and uses thereof." This patent features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. The patent also discloses methods of treating BAF complex-related disorders, such as cancer.

Career Highlights

Richard Caldwell is associated with Foghorn Therapeutics Inc., where he applies his expertise in pharmaceutical innovation. His work focuses on developing novel compounds that can address complex medical conditions.

Collaborations

Caldwell collaborates with talented individuals such as Shawn E R Schiller and Solymar Negretti, contributing to a dynamic research environment.

Conclusion

Richard Caldwell's innovative work in pharmaceutical compounds showcases his commitment to advancing medical science and improving treatment options for serious disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…